var data={"title":"Valganciclovir: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Valganciclovir: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7136?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=valganciclovir-patient-drug-information\" class=\"drug drug_patient\">see &quot;Valganciclovir: Patient drug information&quot;</a> and <a href=\"topic.htm?path=valganciclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Valganciclovir: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708869\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hematologic toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, and bone marrow failure including aplastic anemia have been reported in patients treated with valganciclovir.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Impairment of fertility:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Based on animal data, valganciclovir may cause temporary or permanent inhibition of spermatogenesis in males and suppression of fertility in females.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Fetal toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Based on animal data, valganciclovir has the potential to cause birth defects in humans.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Mutagenesis and carcinogenesis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Based on animal data, valganciclovir has the potential to cause cancers in humans.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232941\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Valcyte</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232942\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Valganciclovir;</li>\n      <li>Valcyte</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232963\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiviral Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232945\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cytomegalovirus (CMV) retinitis, treatment (AIDS-related):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer's labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Induction: 900 mg twice daily for 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance: Following induction treatment, or for patients with inactive CMV retinitis who require maintenance therapy: 900 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate dosing (HHS [OI adult 2016]):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Induction: 900 mg twice daily for 14 to 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance: 900 mg once daily; may consider discontinuation of chronic maintenance therapy in patients that have received 3 to 6 months of treatment, have inactive lesions, and CD4 count &gt;100 cells/mm<sup>3</sup> for 3 to 6 months in response to antiretroviral therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CMV, prophylaxis (solid organ transplant recipients):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer's labeling:</i> 900 mg once daily beginning within 10 days of transplantation; continue therapy until 100 days (heart or kidney-pancreas transplant) or 200 days (kidney transplant) post-transplantation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate dosing:</i> 900 mg once daily; duration of prophylaxis is dependent on type of transplant, as well as donor and recipient CMV serostatus (Kotton 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CMV disease (nonsevere), treatment (solid organ transplant recipients) (off-label use):</b> Oral: 900 mg twice daily until 1 or 2 consecutive undetectable CMV viral load samples are obtained (minimum treatment course: 2 weeks) (Kotton 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CMV esophagitis or colitis in HIV-infected patients (off-label use):</b> Oral: Treat initially with ganciclovir IV; once patient is able to absorb and tolerate oral therapy, may switch to oral valganciclovir 900 mg twice daily for a total duration of 21 to 42 days, or until signs and symptoms have resolved (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CMV, preemptive therapy (hematopoietic cell transplant recipients) (off-label use) (Tomblyn 2009): </b>Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>&lt;100 days post-transplant:</i> 900 mg twice daily for 7 days (autologous transplant) or 7 to 14 days (allogenic transplant), then 900 mg once daily for 1 to 2 weeks or until the indicator test is negative (minimum total induction and maintenance treatment is 2 weeks when 14 days of twice daily is used and 3 weeks when a 7-day induction course is used)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>&gt;100 days post-transplant:</i> 900 mg twice daily for 7 to 14 days, then 900 mg once daily for 1 to 2 weeks or until the indicator test is negative</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CMV, secondary prophylaxis (solid organ transplant recipients) (off-label use): </b>Oral: 900 mg once daily for 1 to 3 months after completion of treatment for CMV disease (Kotton 2013)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9515067\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=valganciclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Valganciclovir: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants, Children, and Adolescents 1 month to 16 years:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>CMV disease (prophylaxis) following heart transplantation:</b> Oral: Dose (mg) = 7 x body surface area x creatinine clearance (see Calculation below) once daily beginning within 10 days of transplantation; continue therapy until 100 days post-transplantation. Doses should be rounded to the nearest 10 mg increment; maximum dose: 900 mg daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants, Children, and Adolescents 4 months to 16 years:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>CMV disease (prophylaxis) following kidney transplantation:</b> Oral: Dose (mg) = 7 x body surface area x creatinine clearance (see Calculation below)  once daily beginning within 10 days of transplantation; continue therapy until 200 days post-transplantation. Doses should be rounded to the nearest 10 mg increment; maximum dose: 900 mg daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Calculation of creatinine clearance:</b> CrCl (mL/minute/1.73 m<sup>2</sup>) = [k x Height (cm)] divided by serum creatinine (mg/dL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> If the calculated CrCl is &gt;150 mL/minute/1.73 m<sup>2</sup>, then a maximum value of 150 mL/minute/1.73 m<sup>2</sup> should be used to calculate the dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Calculated using <i>modified</i> Schwartz formula where k is as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants with low birth weight for gestational age: k = 0.33</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants with birth weight appropriate for gestational age: k = 0.45</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 1 to &lt;2 years: k = 0.45</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Girls 2 to 16 years: k = 0.55</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Boys 2 to &lt;13 years: k = 0.55</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Boys 13 to 16 years: k = 0.7 </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adolescents &gt;16 years: Oral: Refer to adult dosing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232946\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232947\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infants, Children, and Adolescents 1 month to 16 years: No dosage adjustment necessary; calculation for pediatric dosing adjusts for renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adolescents &gt;16 years and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Induction dose:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;60 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 40 to 59 mL/minute: 450 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 25 to 39 mL/minute: 450 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 10 to 24 mL/minute: 450 mg every 2 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;10 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Manufacturer labeling:</i> Use not recommended; ganciclovir (with appropriately specified renal dosage adjustment) should be used instead of valganciclovir</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Alternate dosing:</i> HIV-1 infected persons: Consider valganciclovir solution 200 mg 3 times weekly (Lucas, 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">End stage renal disease (ESRD) on intermittent hemodialysis (IHD):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Manufacturer labeling:</i> Use not recommended; ganciclovir (with appropriately specified renal dosage adjustment) should be used instead of valganciclovir.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Alternate dosing:</i> HIV-1 infected persons: Consider valganciclovir solution 200 mg 3 times weekly (Lucas, 2014); valganciclovir is dialyzable and should be administered following dialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance/prevention dose:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;60 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 40 to 59 mL/minute: 450 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 25 to 39 mL/minute: 450 mg every 2 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 10 to 24 mL/minute: 450 mg twice weekly</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;10 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Manufacturer labeling:</i> Use not recommended; ganciclovir (with appropriately specified renal dosage adjustment) should be used instead of valganciclovir </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Alternate dosing</i>: HIV infected persons: Consider valganciclovir solution 100 mg 3 times weekly (Lucas, 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">End stage renal disease (ESRD) on intermittent hemodialysis (IHD):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Manufacturer labeling:</i> Use not recommended; ganciclovir (with appropriately specified renal dosage adjustment) should be used instead of valganciclovir.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Alternate dosing:</i> HIV-1 infected persons: Consider valganciclovir solution: 100 mg 3 times weekly (Lucas, 2014); valganciclovir is dialyzable and should be administered following dialysis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10818242\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232917\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Valcyte: 50 mg/mL (88 mL) [contains saccharin sodium, sodium benzoate; tutti-frutti flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/mL (88 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Valcyte: 450 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 450 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232903\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232919\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Valganciclovir should be administered with meals. Do not break or crush tablets. The preferred dosage form for pediatric patients is the oral solution; however, valganciclovir tablets may be used so long as the calculated dose is within 10% of the available tablet strength (450 mg).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132847\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232918\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cytomegalovirus, prophylaxis (solid organ transplant recipients):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prevention of cytomegalovirus (CMV) in high-risk adult patients (donor CMV seropositive/recipient CMV seronegative) undergoing kidney, heart, or kidney/pancreas transplantation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prevention of CMV in high risk pediatric patients undergoing kidney transplant (age 4 months to 16 years) or heart transplant (age 1 month to 16 years)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CMV retinitis, treatment (AIDS-related):</b> Treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49367238\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Cytomegalovirus disease, treatment (solid organ transplant recipients):; CMV esophagitis or colitis treatment in HIV-infected patients (adolescents and adults); CMV, preemptive therapy (hematopoietic cell transplant recipients); CMV, secondary prophylaxis (solid organ transplant recipients):</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232970\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Valcyte may be confused with Valium, Valtrex</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ValGANciclovir may be confused with acyclovir, valACYclovir, ganciclovir</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232909\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (12% to 18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (6% to 22%), insomnia (6% to 20%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (16% to 41%), nausea (8% to 30%), vomiting (3% to 21%), abdominal pain (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (&le;31%), thrombocytopenia (&le;22%), neutropenia (3% to 19%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Graft rejection (24%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Tremor (12% to 28%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Retinal detachment (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (S<sub>cr </sub>&gt;1.5 to 2.5 mg/dL: 12% to 50%; S<sub>cr </sub> &gt;2.5: 3% to 17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (9% to 31%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (&ge;5%), peripheral edema (&ge;5%), cardiac arrhythmia (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Peripheral neuropathy (9%), paresthesia (&le;8%), anxiety (&ge;5%), chills (&ge;5%), depression (&ge;5%), dizziness (&ge;5%), fatigue (&ge;5%), malaise (&ge;5%), pain (&ge;5%), agitation (&lt;5%), confusion (&lt;5%), hallucination (&lt;5%), psychosis (&lt;5%), seizure (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Dermatitis (&ge;5%), increased wound secretion (&ge;5%), night sweats (&ge;5%), pruritus (&ge;5%), cellulitis (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hyperkalemia (&ge;5%), hypophosphatemia (&ge;5%), weight loss (&ge;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal distention (&ge;5%), constipation (&ge;5%), decreased appetite (&ge;5%), dyspepsia (&ge;5%), oral mucosa ulcer (&ge;5%), dysgeusia (&lt;5%), pancreatitis (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Hematuria (&ge;5%), urinary tract infection (&ge;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Bone marrow depression (&lt;5%; including aplastic anemia), febrile neutropenia (&lt;5%), hemorrhage (&lt;5%; associated with thrombocytopenia), pancytopenia (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hepatic insufficiency (&ge;5%), increased serum ALT (&lt;5%), increased serum AST (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Organ transplant rejection (6% to 9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Candidiasis (&ge;5%; including oral candidiasis), influenza (&ge;5%), wound infection (&ge;5%), sepsis (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (&ge;5%), back pain (&ge;5%), muscle spasm (&ge;5%), myalgia (&ge;5%), weakness (&ge;5%), limb pain (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Eye pain (&ge;5%), macular edema (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Deafness (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Decreased creatinine clearance (&ge;5%), renal impairment (&ge;5%), renal failure (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (&ge;5%), dyspnea (&ge;5%), pharyngitis (&ge;5%; including nasopharyngitis), upper respiratory tract infection (&ge;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Postoperative complication (&ge;5%), postoperative pain (&lt;5%), wound dehiscence (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined: Genitourinary: Reduced fertility</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing and/or case reports: Agranulocytosis, anaphylaxis, granulocytopenia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232922\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity (eg, anaphylaxis) to valganciclovir, ganciclovir, or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to acyclovir or valacyclovir</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232907\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute renal failure: Acute renal failure may occur; ensure adequate hydration and use with caution in patients receiving concomitant nephrotoxic agents.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood dyscrasias: <b>[US Boxed Warning]: Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, and bone marrow failure, including aplastic anemia have been reported.</b> May occur at any time during treatment and worsen with continued use; cell counts usually begin to recover within 3 to 7 days of treatment discontinuation. Do not use in patients with an absolute neutrophil count &lt;500 cells/mm<sup>3</sup>, platelet count &lt;25,000/mm<sup>3</sup>, or hemoglobin &lt;8 g/dL; use with caution in patients with preexisting bone marrow suppression, cytopenias, or in those receiving myelosuppressive drugs/irradiation. Monitor CBC and platelet count at baseline and frequently during therapy, especially in patients with renal impairment, those with previous drug-induced leukopenia, and those with neutrophil counts &lt;1,000 cells/mm<sup>3</sup> at treatment initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Carcinogenic/teratogenic: <b>[US Boxed Warning]: May cause temporary or permanent inhibition of spermatogenesis and suppression of fertility; has the potential to cause birth defects and cancers in humans.</b> Due to its teratogenic potential, females should undergo pregnancy testing prior to initiation and use effective contraception during treatment and for 30 days after; males should use barrier contraception during treatment and for 90 days after.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with impaired renal function; dosage adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Acute renal failure may occur in elderly patients with or without preexisting renal impairment; use with caution and adjust dose as needed based on renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Liver transplant recipients: Not indicated for use in liver transplant patients (higher incidence of tissue-invasive cytomegalovirus [CMV] relative to oral ganciclovir was observed in trials).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: The preferred dosage form for pediatric patients is the oral solution; however, valganciclovir tablets may be used so long as the calculated dose is within 10% of the available tablet strength (450 mg). Use of valganciclovir for the treatment of congenital CMV disease has not been evaluated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300203\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232911\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10058&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: Ganciclovir-Valganciclovir may enhance the nephrotoxic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Ganciclovir-Valganciclovir may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Didanosine: Ganciclovir-Valganciclovir may increase the serum concentration of Didanosine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imipenem: Ganciclovir-Valganciclovir may enhance the adverse/toxic effect of Imipenem. Specifically, the risk of seizures may be increased.  Management: Avoid concomitant use of these agents unless the prospective benefits of therapy outweigh the risks.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: May increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Mycophenolate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Ganciclovir-Valganciclovir.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenofovir Products: May increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Tenofovir Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zidovudine: Ganciclovir-Valganciclovir may enhance the adverse/toxic effect of Zidovudine. Specifically, hematologic toxicity may be enhanced. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232937\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Coadministration with a high-fat meal increased AUC by 30%. Management: Valganciclovir should be taken with meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232925\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">\n      <b>[US Boxed Warning]: May cause temporary or permanent inhibition of spermatogenesis and suppression of fertility; has the potential to cause birth defects in humans.</b> Valganciclovir is converted to ganciclovir and shares its reproductive toxicity. Ganciclovir crosses the placenta. Based on animal data, temporary or permanent impairment of fertility may occur in males and females. Ganciclovir is also teratogenic in animals. The manufacturer recommends females of reproductive potential undergo pregnancy testing prior to therapy. Females should use effective contraception during treatment and for 30 days after; males should use barrier contraception during treatment and for 90 days after.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Adverse events following congenital cytomegalovirus (CMV) infection may also occur. Hearing loss, mental retardation, microcephaly, seizures, and other medical problems have been observed. The indications for treating CMV retinitis during pregnancy are the same as in non-pregnant HIV infected woman; however systemic therapy should be avoided during the first trimester when possible. Use of valganciclovir is recommended to treat maternal infection, but not recommended for the treatment of asymptomatic maternal disease for the sole purpose of preventing infant infection. Monitoring of the fetus is recommended. Current recommendations for use of valganciclovir in HIV infected pregnant women are based on data from ganciclovir use in pregnant women following organ transplant or use late in pregnancy in non-HIV infected women (HHS [OI adult 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232926\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if ganciclovir or valganciclovir are present in breast milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer. Females with HIV infection should completely avoid breastfeeding to decrease the potential transmission of HIV (HHS [perinatal] 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232927\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Should be taken with meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232915\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC, platelet count, serum creatinine at baseline and periodically during therapy; monitor CBC and platelet count more frequently during therapy in patients with renal impairment, those with previous drug-induced leukopenia, and those with neutrophil counts &lt;1,000 cells/mm<sup>3</sup> at treatment initiation; pregnancy test prior to initiation in females of reproductive potential.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232906\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Valganciclovir is rapidly converted to ganciclovir in the body. Ganciclovir is phosphorylated to a substrate which competitively inhibits the binding of deoxyguanosine triphosphate to DNA polymerase resulting in inhibition of viral DNA synthesis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232921\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Well absorbed; high-fat meal increases AUC by 30%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: Ganciclovir: 0.7 L/kg; widely to all tissue including CSF and ocular tissue</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Ganciclovir: 1% to 2%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Converted to ganciclovir by intestinal mucosal cells and hepatocytes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: With food: 60%; similar in pediatric patients 4 months to 16 years; neonates: Initial data: 54% (Acosta 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric patients (heart, kidney, or liver transplant): Mean range:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">4 months to 2 years: 2.8 to 4.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">2 to 12 years: 2.8 to 3.8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">12 to 16 years: 4.9 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ganciclovir: 4.08 hours; prolonged with renal impairment; Severe renal impairment: Up to 68 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Heart, kidney, kidney-pancreas, or liver transplant patients: Mean range: 6.18 to 6.77 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Ganciclovir: 1.7 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (80% to 90%; primarily as ganciclovir)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232924\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Valcyte Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (88 mL): $1,284.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (ValGANciclovir HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (88 mL): $1,000.33</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Valcyte Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">450 mg (60): $6,364.97</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (ValGANciclovir HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">450 mg (60): $3,863.81</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232928\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ganzos (LK);</li>\n      <li>Rovalcyte (FR);</li>\n      <li>RoValcyte (PT);</li>\n      <li>Vagacyte (LK);</li>\n      <li>Valcyte (AE, AT, AU, BB, BE, BG, BH, BR, CH, CN, CR, CY, CZ, DE, DK, DO, EE, ES, FI, GB, GR, GT, HN, HR, IE, IL, IS, IT, JO, KR, KW, LB, LK, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PH, PL, QA, RO, SA, SE, SG, SI, SK, SV, TH, TR, TW, VN);</li>\n      <li>Valixa (AR, CL, CO, JP, PE, PY, UY, VE);</li>\n      <li>Valtsyt (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Acosta EP, Brundage RC, King JR, et al. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. <i>Clin Pharmacol Ther</i>. 2007;81(6):867-872.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/17392728/pubmed\" target=\"_blank\" id=\"17392728\">17392728</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed June 5, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. <i>Transplantation</i>. 2013;96(4):333-360.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/23896556/pubmed\" target=\"_blank\" id=\"23896556\">23896556</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ljungman P, de La Camara R, Milpied N, et al, &ldquo;Randomized Study of Valacyclovir as Prophylaxis Against Cytomegalovirus Reactivation in Recipients of Allogeneic Bone Marrow Transplants,&rdquo; <i>Blood</i>, 2002, 99(8):3050-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/11929799/pubmed\" target=\"_blank\" id=\"11929799\">11929799</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucas GM, Ross MJ, Stock PG,et al. Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(9):e96-e138. doi: 10.1093/cid/ciu617.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/25234519/pubmed\" target=\"_blank\" id=\"25234519\">25234519</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pescovitz MD, Rabkin J, Merion RM, et al, &ldquo;Valganciclovir Results in Improved Oral Absorption of Ganciclovir in Liver Transplant Recipients,&rdquo; <i>Antimicrob Agents Chemother</i>, 2000, 44(10):2811-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/10991864/pubmed\" target=\"_blank\" id=\"10991864\">10991864</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. <i>Biol Blood Marrow Transplant</i>. 2009;15(10):1143-1238.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/19747629/pubmed\" target=\"_blank\" id=\"19747629\">19747629</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services Panel on Treatment of Pregnant Women With HIV Infection and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs in pregnant women with HIV infection and interventions to reduce perinatal HIV transmission in the United States. <a href=\"https://aidsinfo.nih.gov/guidelines/html/3/perinatal/0\" target=\"_blank\">https://aidsinfo.nih.gov/guidelines/html/3/perinatal/0</a>. Updated November 14, 2017. Accessed December 21, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Valcyte (valganciclovir) [prescribing information]. South San Francisco, CA: Genetech Inc; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Valcyte (valganciclovir) [product monograph]. Mississauga, Ontario, Canada: Hoffman-La Roche ltdc; December 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10058 Version 170.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708869\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F232941\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F232942\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F232963\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F232945\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F9515067\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F232946\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F232947\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F10818242\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F232917\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F232903\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F232919\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132847\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F232918\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F49367238\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F232970\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F232909\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F232922\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F232907\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300203\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F232911\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F232937\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F232925\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F232926\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F232927\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F232915\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F232906\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F232921\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F232924\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F232928\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10058|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=valganciclovir-patient-drug-information\" class=\"drug drug_patient\">Valganciclovir: Patient drug information</a></li><li><a href=\"topic.htm?path=valganciclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">Valganciclovir: Pediatric drug information</a></li></ul></div></div>","javascript":null}